Shots:

• The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & Merck will share global development & commercialization costs (60%/40%) respectively
• For oral products- Gilead will lead commercialization in the US & Merck will lead in the EU & ROW while for injectables- commercialization will be vice versa. Additionally- each company will exercise its option to acquire the license for an investigational oral integrase inhibitor of the other company- following completion of the first P-I trial
• Upon exercise of an option- the companies will split development cost & revenues- unless the non-exercising company decides to opt-out. Both companies’ integrase inhibitors are currently in preclinical development

 ­ Ref: Businesswire | Image: Gilead